ASCO GU 2024 Expert Analysis

CE / CME

Expert Analysis of Key Studies at the 2024 ASCO Genitourinary Cancers Symposium

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits

Nurses: 1.50 Nursing contact hours

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: March 25, 2024

Expiration: March 24, 2025

Terence Friedlander
Terence Friedlander, MD
Rana R. McKay
Rana R. McKay, MD

Activity

Progress
1 2
Course Completed

References

  1. Hussain MHA, Kocherginsky M, Agarwal N, et al. BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm). Presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium; January 25-27, 2024. Abstract 19.
  2. Abiraterone [prescribing information]. New Brunswick, NJ: Johnson & Johnson; 2020.
  3. Olaparib [prescribing information]. Rahway, NJ: AstraZeneca; 2023.
  4. Clarke NW, Armstrong AJ, Thiery-Vuillemin A, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 2022;1:EVIDoa2200043.
  5. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: prostate cancer. v.2.2024. nccn.org. Accessed March 11, 2024.
  6. Agarwal N, Azad Arun, Carles Joan, et al. CONTACT-2: phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium; January 25-27, 2024. Abstract 18.
  7. Cabozantinib [prescribing information]. Alameda, CA: Exelixis, Inc; 2023.
  8. Noori M, Azizi S, Mahjoubfar A, et al. Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis. Front Immunol. 2023;14:1181051.
  9. Lanka SM, Zorko NA, Antonarakis ES, Barata PC. Metastatic castration-resistant prostate cancer, immune checkpoint inhibitors, and beyond. Curr Oncol. 2023;30:4246-4256.
  10. Smith M, De Bono J, Sternberg C, et al. Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. J Clin Oncol. 2016;34:3005-3013.
  11. Basch EM, Scholz M, de Bono JS, et al. Cabozantinib versus mitoxantrone-prednisone in symptomatic metastatic castration-resistant prostate cancer: a randomized phase 3 trial with a primary pain endpoint. Eur Urol. 2019;75:929-937.
  12. Khalaf DJ, Annala M, Taavitsainen S, et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol. 2019;20:1730-1739.
  13. Liu JM, Lin CC, Liu KL, et al. Second-line hormonal therapy for the management of metastatic castration-resistant prostate cancer: a real-world data study using a claims database. Sci Rep. 2020;10:4240.
  14. Hennequin C, Sargos P, Roca L, et al. Long-term results of dose escalation (80 vs 70 Gy) combined with long-term androgen deprivation in high-risk prostate cancers: GETUG-AFU 18 randomized trial. Presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium; January 25-27, 2024. Abstract LBA259.
  15. McBride SM, Anderson EM. The use of androgen deprivation therapy in combination with radiation for localized prostate cancer. Front Urol. 2022;2:890814.
  16. Puca L, Gavyert K, Sailer V, et al. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci Transl Med. 2019;11.
  17. Molloy ME, Valenzuela LB, Wu C-H, et al. Long-term anti-tumor immunity induced by of HPN328, a DLL3-targeting trispecific, half-life extended T cell engager, in a preclinical immunocompetent mouse model. Presented at: American Association for Cancer Research Annual Meeting; April 14-19, 2023.
  18. Beltran H, Dowlati A, Jain P, et al. Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN). Presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium; January 25-27, 2024. Abstract 121.
  19. Shimabukuro-Vornhagen A, Godel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6:56.
  20. Van Der Heijden MS, Powles T, Gupta S, et al. Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study. Presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium; January 25-27, 2024. Abstract LBA530.
  21. Powles T, Valderrama BP, Gupta S, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390:875-888.
  22. Powles T, Perez-Valderrama B, Gupta S, et al. EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab vs chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma. Presented at: European Society for Medical Oncology Congress; October 20-24, 2023. Abstract LBA6.
  23. Hoffman-Censits J, Maldonado L. Targeted treatment of locally advanced and metastatic urothelial cancer: enfortumab vedotin in context. Onco Targets Ther. 2022;15:1519-1529.
  24. Fu Z, Gao C, Wu T, et al. Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates. iScience. 2023;26:107778.
  25. van der Heijden MS, Sonpavde G, Powles T, et al. Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med. 2023;389:1778-1789.
  26. Ibrahim EY, Ehrlich BE. Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings. Crit Rev Oncol Hematol. 2020;145:102831.
  27. Apolo AB, Ballman KV, Sonpavde GP, et al. AMBASSADOR Alliance A031501: phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation. Presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium; January 25-27, 2024. Abstract LBA531.
  28. Bersanelli M, Buti S, Giannatempo P, et al. Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;159:103241.
  29. Rizzo A, Mollica V, Massari F. Expression of programmed cell death ligand 1 as a predictive biomarker in metastatic urothelial carcinoma patients treated with first-line immune checkpoint inhibitors versus chemotherapy: A systematic review and meta-analysis. Eur Urol Focus. 2022;8:152-159.
  30. Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021;384:2102-2114.
  31. Bellmunt J, Hussain M, Gschwend JE, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:525-537.
  32. Jain RK, Swami U, Bilen MA, et al. Cabozantinib plus pembrolizumab as first-line therapy for cisplatin-ineligible advanced urothelial carcinoma (PemCab). Presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium; January 25-27, 2024. Abstract 539.
  33. Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021a;384:829-841.
  34. Hoeh B, Flammia RS, Hohenhorst L, et al. IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time. Semin Oncol. 2022;49:394-399.
  35. Necchi A, Mariani L, Zaffaroni N, et al. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol. 2012;13:810-816.
  36. Galsky MD, Sfakianos JP, Ye D, et al. Oral APL-1202 in combination with tislelizumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC): Interim analysis of ANTICIPATE phase II trial. Presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium; January 25-27, 2024. Abstract 632.
  37. Shim JS, Matsui Y, Bhat S, et al. Effect of nitroxoline on angiogenesis and growth of human bladder cancer. J Natl Cancer Inst. 2010;102:1855-1873.
  38. Goel S, Sinha RJ, Bhaskar V, Aeron R, Sharma A, Singh V. Role of gemcitabine and cisplatin as neoadjuvant chemotherapy in muscle invasive bladder cancer: Experience over the last decade. Asian J Urol. 2019;6:222-229.
  39. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: bladder cancer. v.1.2024. nccn.org. Accessed March 11, 2024.
  40. Jiang CY, Hwang H, Jindal T, et al. Sequencing of erdafitinib (erda) and enfortumab vedotin (EV) in patients (pts) with fibroblast growth factor receptor (FGFR2/3) altered (alt) advanced urothelial cancer (aUC): Analysis of UNITE database. Presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium; January 25-27, 2024. Abstract 616.
  41. Enfortumab vedotin [prescribing information]. Northbrook IL: Astellas Pharma US, Inc. and Bothell, WA: Seagen Inc; 2023.
  42. Erdafitinib [prescribing information]. Horsham, PA: Janssen Products, LP; 2024.
  43. Choueiri TK, Tomczak P, Park SH, et al. Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC). Presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium; January 25-27, 2024. Abstract LBA359.
  44. Choueiri TK, Tomczak P, Park SH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385:683-694.
  45. Powles T, Tomczak P, Park SH, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:1133-1144.
  46. Motzer RJ, Bex A, Russo P, et al. Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial. Presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium; January 25-27, 2024. Abstract LBA358.
  47. Motzer RJ, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23:888-898.
  48. Bourlon MT, Escudier B, Burotto M, al e. Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial. Presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium; January 25-27, 2024. Abstract 362.
  49. Tannir NM, Escudier B, McDermott DF, et al. Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial. Presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium; January 25-27, 2024. Abstract 363.
  50. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277-1290.
  51. Motzer RJ, McDermott DF, Escudier B, et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer. 2022;128:2085-2097.
  52. George S, Bourlon MT, Chacon MR, et al. Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T. Presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium; January 25-27, 2024. Abstract LBA360.